List of Excipients in Branded Drug DURAGESIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	DURAGESIC	fentanyl	50458-101	ISOPROPYL MYRISTATE

DURAGESIC Excipient Strategy and Commercial Opportunities in Fentanyl Transdermal Patches

Last updated: September 11, 2026

DURAGESIC is a fentanyl transdermal system delivering fentanyl continuously for up to 72 hours. The core excipient opportunity is not a new active ingredient. It is improved control of adhesion, fentanyl flux, heat stability, extractables, tamper resistance, skin tolerability, and manufacturing yield. The original reservoir-patch architecture is mature and largely exposed to generic competition, while differentiated matrix systems, safer adhesives, and abuse-resistant packaging offer more defensible commercial positions.

What is DURAGESIC and how does its transdermal system work?

DURAGESIC contains fentanyl, a Schedule II opioid, in a patch designed for continuous systemic delivery through intact skin. Current labeled strengths are 12, 25, 50, 75, and 100 mcg per hour, with intended replacement every 72 hours in appropriate opioid-tolerant patients.[1]

The original DURAGESIC construction uses multiple functional layers:

Patch component	Function	Representative material or formulation role
Backing layer	Protects the system from the external environment	Polyester or comparable occlusive polymer film
Drug reservoir	Holds fentanyl and controls its available concentration	Fentanyl with alcohol, hydroxyethyl cellulose, and purified water in the original reservoir design
Rate-controlling membrane	Regulates movement of fentanyl from the reservoir	Ethylene-vinyl acetate membrane
Adhesive layer	Maintains skin contact	Silicone-based adhesive system in the original design
Protective liner	Covers the adhesive before use	Removable polymer liner

The exact excipient composition depends on the product architecture and manufacturer. Generic fentanyl patches may use reservoir, matrix, or drug-in-adhesive designs. FDA labeling for each product, rather than the DURAGESIC label alone, controls the relevant inactive-ingredient profile.[1,2]

The commercial objective is to maintain the labeled fentanyl delivery rate while improving patch handling, adhesion, tolerability, and resistance to misuse.

What excipients are used in the DURAGESIC patch?

The original DURAGESIC reservoir design identifies fentanyl, alcohol USP, hydroxyethyl cellulose, and purified water in the drug reservoir. The device also relies on polymeric materials for the backing, membrane, adhesive, and protective liner.[1]

Hydroxyethyl cellulose

Hydroxyethyl cellulose functions as a viscosity-modifying and reservoir-structuring excipient. It can help suspend or retain fentanyl in the reservoir and influence the rate at which the drug contacts the controlling membrane.

Commercial development opportunities include:

• tighter molecular-weight distribution;
• lower bioburden and endotoxin specifications;
• improved compatibility with ethanol-containing reservoirs;
• reduced batch-to-batch viscosity variation;
• controlled hydration behavior;
• lower extractables and leachables.

Hydroxyethyl cellulose is established in pharmaceutical manufacturing, so the strongest value proposition is usually process consistency rather than novelty.

Ethanol

Alcohol USP acts as a solvent and may increase fentanyl mobility within the reservoir. It can also affect skin permeation, solvent evaporation, package compatibility, and long-term drug stability.

Ethanol creates several development constraints:

• volatile loss during manufacture or storage;
• seal integrity requirements;
• interaction with polymeric membranes and adhesives;
• potential changes in fentanyl flux over shelf life;
• flammability controls during production;
• residual-solvent and packaging qualification.

A supplier that can provide pharmaceutical-grade ethanol with controlled water content, low aldehydes, and reliable supply continuity can compete on quality and manufacturing performance. The excipient itself is not likely to create meaningful composition-of-matter exclusivity.

Polymeric membranes

The rate-controlling membrane is one of the most technically important components. Ethylene-vinyl acetate composition, thickness, crystallinity, and permeability affect fentanyl release.

Potential commercial differentiators include:

• lower variation in vinyl acetate content;
• tighter thickness tolerances;
• improved puncture resistance;
• better compatibility with reservoir solvents;
• reduced fentanyl adsorption;
• validated performance after exposure to heat and moisture.

Membrane suppliers can obtain stronger commercial protection through proprietary grades, multilayer constructions, and manufacturing specifications than through a generic claim to ethylene-vinyl acetate itself.

Adhesives

Adhesion is a major failure point for transdermal opioid patches. A patch that lifts, wrinkles, or detaches can produce underdosing, accidental exposure, or a need for replacement.

Adhesive development must balance:

• adhesion over 72 hours;
• low skin irritation;
• low sensitization risk;
• compatibility with fentanyl and solvents;
• resistance to sweat and bathing;
• controlled peel force;
• minimal residue after removal;
• performance across age groups and skin types.

Silicone, polyisobutylene, acrylic, and hybrid adhesive systems are commercially relevant. A drug-in-adhesive matrix can reduce the number of layers and simplify manufacturing, but it may change fentanyl crystallization, drug loading, cold flow, and release behavior.

What excipient strategies create the strongest commercial opportunities?

The most attractive opportunities are in functional excipients and engineered components that solve measurable performance problems.

Opportunity	Technical objective	Commercial attractiveness	Main regulatory burden
High-performance silicone adhesive	Maintain 72-hour adhesion with low irritation	High	Adhesion, irritation, sensitization, extractables
Low-variation EVA membrane	Improve fentanyl flux consistency	Medium-high	Release testing and process validation
Anti-crystallization matrix	Prevent fentanyl precipitation	High	Stability and dose-uniformity studies
Heat-resistant adhesive system	Reduce dose dumping risk during heat exposure	High	In vitro and clinical performance assessment
Tamper-resistant patch construction	Limit fentanyl recovery from used or unused patches	High	Human-factors and abuse-related testing
Low-extractables backing film	Improve chemical compatibility	Medium	Leachables and toxicological qualification
Skin-friendly removal layer	Reduce dermatitis and residue	Medium	Irritation and sensitization testing
Automated coating formulation	Improve yield and reduce waste	Medium-high	Process validation and comparability

The strongest near-term opportunity is a solvent-compatible adhesive or matrix platform that supports consistent fentanyl delivery without increasing skin reactions. A platform that can be adapted to buprenorphine, clonidine, estradiol, rivastigmine, or other transdermal products can support broader licensing revenue.

What formulation patents protect DURAGESIC and generic fentanyl patches?

The original fentanyl transdermal patent estate included claims directed to transdermal delivery systems, reservoirs, membranes, adhesives, and controlled release. U.S. Patent No. 4,588,580, associated with fentanyl transdermal delivery, expired years ago.[3]

The practical consequence is that the basic concept of delivering fentanyl through a patch is open to generic competition. Current protection is more likely to arise from:

• specific patch architectures;
• adhesive compositions;
• multilayer constructions;
• manufacturing methods;
• low-residual-solvent processes;
• tamper-resistant designs;
• packaging and disposal systems;
• improved methods of treating pain or managing opioid exposure.

A new formulation patent must provide a meaningful technical distinction. A claim directed only to substituting one conventional adhesive for another may face obviousness and written-description challenges. Stronger claims would link a defined composition to an unexpected result, such as stable 72-hour delivery after elevated-temperature exposure or materially lower skin irritation.

When does DURAGESIC lose exclusivity?

DURAGESIC has already lost practical market exclusivity for its core fentanyl transdermal technology. Fentanyl patches are available through abbreviated new drug application pathways, subject to FDA approval, controlled-substance requirements, manufacturing compliance, and product-specific bioequivalence or performance standards.[2,4]

The commercial exclusivity timeline is:

Event	Status
Original DURAGESIC approval	Historical NDA approval
Core transdermal technology	Patent protection expired
Generic entry	Established
Small-molecule biosimilar pathway	Not applicable
Brand-only pricing power	Materially reduced
Remaining protection	Product-specific formulation, process, device, packaging, and use claims

DURAGESIC does not have biosimilar risk because fentanyl is a small molecule. The relevant competitors are generic transdermal systems and alternative opioid or non-opioid delivery technologies.

What is the Orange Book status of DURAGESIC?

The Orange Book is relevant because approved fentanyl transdermal products may have listed patents, exclusivity information, and therapeutic-equivalence designations.[2] The original DURAGESIC patents do not provide a current barrier to generic competition.

For an excipient supplier, the key Orange Book issue is not whether an excipient is listed as an active patent claim. It is whether the customer’s finished product contains a protected formulation or method-of-use element that could generate Paragraph IV litigation.

A generic sponsor developing a new adhesive or matrix should evaluate:

1. current Orange Book listings for the reference product;
2. patents associated with competing generic products;
3. formulation patents covering the proposed patch architecture;
4. method-of-use patents covering opioid-tolerant patients or dosing intervals;
5. device and packaging patents outside the Orange Book;
6. freedom to operate in the United States, Europe, Canada, Japan, and other controlled-substance markets.

Which companies are challenging or competing with DURAGESIC?

Competition comes from generic manufacturers rather than biosimilar developers. The market has included large generic companies and specialized transdermal manufacturers operating under ANDAs. Product availability varies by strength, country, supply conditions, and controlled-substance quotas.

The main competitive categories are:

• authorized or branded fentanyl patches;
• conventional generic reservoir patches;
• matrix fentanyl patches;
• drug-in-adhesive systems;
• compounded or hospital-use alternatives, where legally permitted;
• non-opioid transdermal products;
• long-acting injectable or oral opioid alternatives.

Companies that control a reliable fentanyl patch platform can compete on supply continuity, hospital contracts, low-defect rates, and consistent release performance. Price alone is less durable because multiple generic suppliers can enter once regulatory and manufacturing requirements are satisfied.

What Paragraph IV challenges and litigation risks affect fentanyl patches?

Paragraph IV risk is concentrated in later-developed generic formulations and patents covering specific delivery systems. A generic applicant may certify that a listed patent is invalid, unenforceable, or not infringed. The patent holder can then bring litigation that may trigger a regulatory stay under the Hatch-Waxman framework.[4]

For an excipient platform, the principal litigation risks are:

• infringement of adhesive-composition claims;
• infringement of membrane or multilayer claims;
• patent claims covering fentanyl crystallization control;
• process claims for coating and drying;
• claims covering dose delivery after heat exposure;
• trade-secret disputes involving coating conditions or polymer grades.

Settlement agreements are product-specific and should not be assumed from the existence of generic market entry. A supplier should separate patent expiration from contractual freedom to operate. A product may be legally outside the original DURAGESIC patents but still implicate later patents owned by generic manufacturers or technology suppliers.

How does DURAGESIC compare with other transdermal opioid products?

Attribute	DURAGESIC/fentanyl patch	Buprenorphine patch	Oral extended-release opioid
Delivery route	Transdermal	Transdermal	Oral
Dosing interval	Typically 72 hours	Product-dependent	Usually daily or more frequent
Controlled substance	Schedule II fentanyl	Controlled opioid, classification varies by jurisdiction	Controlled opioid
Main excipient challenge	Flux control and abuse risk	Lower-dose delivery and adhesion	Tablet release and abuse resistance
Heat sensitivity concern	High	Relevant	Relevant but usually different
Generic opportunity	Mature	Product-specific	Broad
Biosimilar exposure	None	None	None

Fentanyl patches require particularly strict control of drug loading and delivery rate because fentanyl is highly potent. A small change in flux, adhesive contact, or heat exposure can have major clinical consequences. This raises the value of validated excipient systems but also increases development and liability costs.

What manufacturing and intellectual-property barriers affect commercial entry?

Manufacturing barriers are more significant than raw-material availability. A successful supplier must support:

• precision coating at low fentanyl concentrations;
• solvent control and drying;
• uniform layer thickness;
• membrane and adhesive lamination;
• seal integrity;
• low particulate burden;
• dose-content uniformity;
• controlled-substance security;
• validated cleaning procedures;
• reconciliation of fentanyl inventory;
• serialization and diversion controls.

The most defensible intellectual property may cover a complete manufacturing process rather than a single excipient. Examples include a coating sequence that prevents fentanyl crystallization, a drying profile that preserves solvent content, or a lamination process that reduces delamination during storage.

What FDA regulatory requirements apply to new excipients for fentanyl patches?

A novel excipient may be reviewed through the finished drug application rather than through a standalone approval pathway. FDA will evaluate the excipient in the context of the proposed route, dose, exposure, manufacturing process, and finished dosage form.[5]

Key data packages include:

• identity and purity;
• impurity profile;
• residual solvents;
• extractables and leachables;
• toxicological qualification;
• skin irritation and sensitization;
• compatibility with fentanyl;
• stability;
• in vitro release;
• permeation performance;
• adhesion and wear studies;
• dose dumping under heat;
• container-closure compatibility;
• manufacturing controls.

For a generic product, a materially different excipient system can create additional equivalence and product-performance work. For a 505(b)(2) product, a differentiated patch may support a new delivery claim, dosing interval, abuse-resistance feature, or patient-use benefit, but it will require a more substantial clinical and regulatory package.[4,5]

What revenue exposure and licensing opportunities exist?

The original DURAGESIC brand has limited ability to capture premium pricing against established generics. The more attractive revenue pools are upstream and platform-based.

Excipient licensing

A supplier can license:

• pressure-sensitive adhesive systems;
• fentanyl-compatible reservoir polymers;
• anti-crystallization excipients;
• heat-resistant matrix systems;
• low-irritation adhesive technologies;
• tamper-resistant patch laminates;
• automated coating and inspection processes.

License economics improve when the platform applies to several transdermal products rather than fentanyl alone.

Contract development and manufacturing

CDMOs can offer:

• formulation screening;
• pilot coating;
• scale-up;
• analytical method development;
• controlled-substance manufacturing;
• stability studies;
• regulatory support;
• commercial packaging.

Controlled-substance handling narrows the field of qualified manufacturers and can support higher service margins.

Geographic expansion

The United States, European Union, Japan, Canada, and Australia have established regulatory frameworks for transdermal fentanyl, but market access, prescription controls, reimbursement, and abuse-prevention expectations differ. A formulation that uses globally accepted excipients and has strong extractables data is more readily transferable across jurisdictions.

Emerging markets may offer volume growth but carry higher risks involving diversion, regulatory enforcement, supply-chain security, and local registration requirements.

How strong is the patent estate for a new DURAGESIC excipient platform?

A new excipient platform has moderate patent potential if it claims a defined composition, a measurable performance result, and a reproducible manufacturing process. The patent estate is weak if it relies on a conventional material used for its ordinary function.

The strongest claim strategy combines:

1. composition claims for the adhesive, membrane, or matrix;
2. functional claims tied to fentanyl delivery;
3. process claims covering coating, drying, or lamination;
4. package or disposal claims addressing residual fentanyl;
5. use claims tied to improved wear time or reduced skin reactions;
6. international filings in major transdermal markets.

Trade-secret protection is especially important for polymer ratios, coating conditions, drying profiles, and quality-control algorithms that may be difficult to detect from the finished patch.

Key Takeaways

• DURAGESIC is a mature fentanyl transdermal product with expired core technology and established generic competition.
• The original reservoir design uses fentanyl, alcohol, hydroxyethyl cellulose, purified water, a rate-controlling polymer membrane, and an adhesive system.
• Adhesion, heat stability, fentanyl crystallization, membrane consistency, and tamper resistance are the highest-value excipient opportunities.
• Biosimilar risk does not apply. Generic and 505(b)(2) competition controls the market.
• New commercial value is more likely to come from differentiated patch platforms, controlled-substance manufacturing, and multi-product licensing than from the DURAGESIC brand itself.
• Strong patent positions require defined materials linked to unexpected delivery, safety, stability, or manufacturing results.
• FDA review will focus on the complete patch system, not the excipient in isolation.

FAQs about DURAGESIC excipients and market entry

Can a new adhesive create a separate patent position for a fentanyl patch?

Yes. A new adhesive can support composition, formulation, process, and use claims when it provides a defined technical benefit such as improved 72-hour adhesion, lower irritation, or stable fentanyl release after heat exposure.

Is fentanyl in a transdermal patch considered a biologic?

No. Fentanyl is a chemically synthesized small molecule. A fentanyl patch follows drug and combination-product requirements, not the biosimilar pathway.

What is the most important excipient for fentanyl patch performance?

The adhesive and rate-controlling membrane usually have the greatest effect on practical product performance. The reservoir composition also affects fentanyl stability, crystallization, and release.

Can a generic manufacturer change the DURAGESIC excipients?

A generic manufacturer may use a different inactive-ingredient system if the product satisfies applicable FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and performance. A material formulation change can increase development and regulatory obligations.

Are unused DURAGESIC patches commercially valuable because they contain residual fentanyl?

Yes. Used and unused patches require controlled handling because residual fentanyl can remain in the system. Disposal, diversion prevention, packaging, and tamper resistance are relevant commercial and regulatory design opportunities.

References

1. U.S. Food and Drug Administration. (n.d.). DURAGESIC- fentanyl patch, extended release prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. United States Patent and Trademark Office. (1986). U.S. Patent No. 4,588,580: Transdermal therapeutic system for administering fentanyl. USPTO.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Amendments to guidance on ANDAs, 505(b)(2) applications, and reference listed drugs. FDA.

5. U.S. Food and Drug Administration. (2019). Chemistry, manufacturing, and controls information for human drug compounding and new drug applications: Transdermal and topical delivery systems. FDA.